BMS Demonstrates Commitment to Hematology and Advancing R&D Across Multiple Blood Cancers Through Immuno-Oncology Leadership

Bristol-Myers Squibb Company (BMS) has announced the presentation of clinical research from its hematology portfolio at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria from 11–14 June. BMS will present data for elotuzumab, an investigational immunostimulatory antibody, in relapsed or refractory multiple myeloma; Opdivo (nivolumab), in patients with relapsed or refractory lymphoid malignancies; and Sprycel (dasatinib), in chronic myeloid leukemia.

Data to be presented at EHA exemplify BMS’s commitment to advancing the treatment of blood cancers through its experience in hematology and its transformative science of Immuno-oncology.

Key oral presentations include:

•  ELOQUENT-2: A Phase III, open-label study [Abstract #S471] comparing elotuzumab in combination with lenalidomide and dexamethasone (ELd) versus lenalidomide and dexamethasone alone (Ld) in patients with relapsed or refractory multiple myeloma, will be featured in the EHA press briefing on Friday 12 June at 8:30 a.m. CEST and will be presented during the Presidential Symposium, also on 12 June, at 3:45 p.m. CEST. The ELOQUENT-2 study was published in the New England Journal of Medicine on 2 June.

•  Study 009: A Phase II, open-label study [Abstract #S103] comparing elotuzumab in combination with bortezomib (a proteasome inhibitor) and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma will be presented in an oral session on 12 June at 12:00 p.m. CEST.

•  PREAMBLE: A preliminary analysis of an ongoing, multinational, observational study [Abstract #S148] evaluating the real-world clinical effectiveness of standard treatments, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), in patients with relapsed or refractory multiple myeloma will be presented in an oral session on 12 June at 12:00 p.m. CEST.

•  CheckMate -039: Updated data from a Phase 1 study [Abstract #S808] evaluating the safety, tolerability and potential efficacy of Opdivo in several hematologic malignancies, including classical Hodgkin Lymphoma will be presented in an oral session on Sunday, June 14 at 8:45 a.m. CEST.

“BMS is leveraging its broad experience in oncology and leading immuno-oncology science to develop a portfolio of innovative therapies, including a novel modality for multiple myeloma, because we believe patients with blood cancers deserve more,” said Michael Giordano, senior vice president, Head of Development, Oncology, BMS. “These data at EHA illustrate our commitment to transforming survival expectations for more patients with a variety of hematologic malignancies.”